A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection.

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, US National Institutes of Health, Bethesda, Maryland, USA.
Nature medicine (Impact Factor: 28.05). 03/2010; 16(3):334-8. DOI: 10.1038/nm.2105
Source: PubMed

ABSTRACT Chikungunya virus (CHIKV) has infected millions of people in Africa, Europe and Asia since this alphavirus reemerged from Kenya in 2004. The severity of the disease and the spread of this epidemic virus present a serious public health threat in the absence of vaccines or antiviral therapies. Here, we describe a new vaccine that protects against CHIKV infection of nonhuman primates. We show that selective expression of viral structural proteins gives rise to virus-like particles (VLPs) in vitro that resemble replication-competent alphaviruses. Immunization with these VLPs elicited neutralizing antibodies against envelope proteins from alternative CHIKV strains. Monkeys immunized with VLPs produced high-titer neutralizing antibodies that protected against viremia after high-dose challenge. We transferred these antibodies into immunodeficient mice, where they protected against subsequent lethal CHIKV challenge, indicating a humoral mechanism of protection. Immunization with alphavirus VLP vaccines represents a strategy to contain the spread of CHIKV and related pathogenic viruses in humans.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Chikungunya virus (CHIKV) is a re-emerging mosquito borne alphavirus that recently caused large epidemics in islands in, and countries around, the Indian Ocean. There is currently no specific drug for therapeutic treatment or for use as a prophylactic agent against infection, and currently there is no commercially available vaccine. Prohibitin has been identified as a receptor protein used by chikungunya virus to enter into mammalian cells. Recently, synthetic sulfonyl amidines and flavaglines, a class of naturally occurring plant compounds with potent anti-cancer and cytoprotective and neuroprotective activities have been shown to interact directly with prohibitin. This study therefore sought to determine whether three prohibitin ligands (sulfonyl amidine 1m and the flavaglines FL3, FL23) were able to inhibit CHIKV infection of mammalian Hek293T/17 cells. All three compounds showed inhibition of infection and reduced virus production when cells were treated before infection but not when added after infection. Pretreatment of cells for only 15 minutes prior to infection followed by washing out of the compound showed significant inhibition of entry and virus production. These results suggest that further investigation of prohibitin ligands as potential Chikungunya virus entry inhibitors is warranted.
    Microbiology and Immunology 02/2015; DOI:10.1111/1348-0421.12230 · 1.31 Impact Factor
  • Source
    J M Medlock, K M Hansford, V Versteirt, B Cull, H Kampen, D Fontenille, G Hendrickx, H Zeller, W Van Bortel, F Schaffner
    [Show abstract] [Hide abstract]
    ABSTRACT: Among the invasive mosquitoes registered all over the world, Aedes species are particularly frequent and important. As several of them are potential vectors of disease, they present significant health concerns for 21st century Europe. Five species have established in mainland Europe, with two (Aedes albopictus and Aedes japonicus) becoming widespread and two (Ae. albopictus and Aedes aegypti) implicated in disease transmission to humans in Europe. The routes of importation and spread are often enigmatic, the ability to adapt to local environments and climates are rapid, and the biting nuisance and vector potential are both an ecomonic and public health concern. Europeans are used to cases of dengue and chikungunya in travellers returning from the tropics, but the threat to health and tourism in mainland Europe is substantive. Coupled to that are the emerging issues in the European overseas territorities and this paper is the first to consider the impacts in the remoter outposts of Europe. If entomologists and public health authorities are to address the spread of these mosquitoes and mitigate their health risks they must first be prepared to share information to better understand their biology and ecology, and share data on their distribution and control successes. This paper focusses in greater detail on the entomological and ecological aspects of these mosquitoes to assist with the risk assessment process, bringing together a large amount of information gathered through the ECDC VBORNET project.
    Bulletin of Entomological Research 03/2015; DOI:10.1017/S0007485315000103 · 1.90 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Chikungunya virus represents a threat to Costa Rica. This arbovirus was introduced to the American continent during the last trimester of 2013. Due to its epidemiological and virological characteristics, as well as to the presence of its vectors in the territory, chikungunya could become the next novel endemic disease in Costa Rica. Although chikungunya has a low mortality rate, its high rate of attack could cause a collapse of the national health system during an epidemic. In this review we summarize the clinical, virological, epidemiological and entomological characteristics associated to chikungunya virus for a proper identification, diagnosis and differentiation of chikungunya fever cases in the country. Furthermore, we emphasize the importance of the epidemiological and vector control in order to prevent epidemics of this disease in Costa Rica.
    Acta médica costarricense 03/2015; 57(1):7-15.

Full-text (2 Sources)

Available from
May 22, 2014